PDCD1 and neutropenia: In direct comparisons of safety analyses, there were no appreciable differences between PD‐1 inhibitors + chemotherapy or PD‐L1 inhibitors + chemotherapy relative to placebo + chemotherapy with any grade of AE, grade ≥ 3 AE, with any grade of neutropenia, grade ≥ 3 neutropenia (a1, b1, c1, and d1 in Figure 4).